These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29047309)

  • 1. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.
    Vitelli A; Folgori A; Scarselli E; Colloca S; Capone S; Nicosia A
    Expert Rev Vaccines; 2017 Dec; 16(12):1241-1252. PubMed ID: 29047309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel vaccine vectors: Chimpanzee adenoviral vectors.
    Guo J; Mondal M; Zhou D
    Hum Vaccin Immunother; 2018 Jul; 14(7):1679-1685. PubMed ID: 29300685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.
    Tatsis N; Blejer A; Lasaro MO; Hensley SE; Cun A; Tesema L; Li Y; Gao GP; Xiang ZQ; Zhou D; Wilson JM; Ertl HC
    Mol Ther; 2007 Mar; 15(3):608-17. PubMed ID: 17228314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.
    Ewer K; Sebastian S; Spencer AJ; Gilbert S; Hill AVS; Lambe T
    Hum Vaccin Immunother; 2017 Dec; 13(12):3020-3032. PubMed ID: 29083948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
    McCoy K; Tatsis N; Korioth-Schmitz B; Lasaro MO; Hensley SE; Lin SW; Li Y; Giles-Davis W; Cun A; Zhou D; Xiang Z; Letvin NL; Ertl HC
    J Virol; 2007 Jun; 81(12):6594-604. PubMed ID: 17428852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimpanzee-origin adenovirus vectors as vaccine carriers.
    Tatsis N; Tesema L; Robinson ER; Giles-Davis W; McCoy K; Gao GP; Wilson JM; Ertl HC
    Gene Ther; 2006 Mar; 13(5):421-9. PubMed ID: 16319951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
    Capone S; D'Alise AM; Ammendola V; Colloca S; Cortese R; Nicosia A; Folgori A
    Expert Rev Vaccines; 2013 Apr; 12(4):379-93. PubMed ID: 23560919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
    Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
    PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.
    Abbink P; Maxfield LF; Ng'ang'a D; Borducchi EN; Iampietro MJ; Bricault CA; Teigler JE; Blackmore S; Parenteau L; Wagh K; Handley SA; Zhao G; Virgin HW; Korber B; Barouch DH
    J Virol; 2015 Feb; 89(3):1512-22. PubMed ID: 25410856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors.
    Roy S; Gao G; Lu Y; Zhou X; Lock M; Calcedo R; Wilson JM
    Hum Gene Ther; 2004 May; 15(5):519-30. PubMed ID: 15144581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel Vaccines Against Infectious Diseases Based on Chimpanzee Adenoviral Vector.
    Zhang C; Chi Y; Zhou D
    Methods Mol Biol; 2017; 1581():3-13. PubMed ID: 28374240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of replication-deficient adenovirus malaria vaccines.
    Hollingdale MR; Sedegah M; Limbach K
    Expert Rev Vaccines; 2017 Mar; 16(3):261-271. PubMed ID: 27606709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys.
    Collignon C; Bol V; Chalon A; Surendran N; Morel S; van den Berg RA; Capone S; Bechtold V; Temmerman ST
    Front Immunol; 2020; 11():579872. PubMed ID: 33329551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.
    Coughlan L
    Front Immunol; 2020; 11():909. PubMed ID: 32508823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simian adenoviruses as vaccine vectors.
    Morris SJ; Sebastian S; Spencer AJ; Gilbert SC
    Future Virol; 2016 Sep; 11(9):649-659. PubMed ID: 29527232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral vectors as vaccine carriers.
    Ertl HC
    Curr Opin Virol; 2016 Dec; 21():1-8. PubMed ID: 27327517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vector-based genetically modified vaccines: Exploiting Jenner's legacy.
    Ramezanpour B; Haan I; Osterhaus A; Claassen E
    Vaccine; 2016 Dec; 34(50):6436-6448. PubMed ID: 28029542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of nonhuman adenoviruses as vaccine vectors.
    Bangari DS; Mittal SK
    Vaccine; 2006 Feb; 24(7):849-62. PubMed ID: 16297508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.
    Peruzzi D; Dharmapuri S; Cirillo A; Bruni BE; Nicosia A; Cortese R; Colloca S; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2009 Feb; 27(9):1293-300. PubMed ID: 19162112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus vectors as recombinant viral vaccines.
    Imler JL
    Vaccine; 1995 Sep; 13(13):1143-51. PubMed ID: 8578797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.